B of A Securities Reiterates Buy Rating on ACADIA Pharmaceuticals
B of A Securities maintains its buy rating on ACADIA Pharmaceuticals with a $30 price target, a 17.74% upside from the current price.
Key Points
- B of A Securities reiterated its buy rating on ACADIA Pharmaceuticals with a $30 price target, as of June 30, 2026.
- B of A Securities's $30 price target implies 17.74% upside from ACADIA Pharmaceuticals Inc.'s ($ACAD) current $25.48 share price.
- Shares of NasdaqGS:ACAD traded near $25.5 on Tuesday, with a market cap of about $4.34 billion and a P/E ratio of 11.46.
- Baker Bros. Advisors LP holds 42.9 million shares, while Vanguard Portfolio Management LLC opened a new position with 8.67 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) received a vote of confidence from B of A Securities, which reiterated its buy rating on the stock with a price target of $30. This move by analyst Tazeen Ahmad on June 30, 2026, comes as shares of ACADIA traded near $25.5 on Tuesday.
B of A Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
ACADIA Pharmaceuticals Inc. Stock Down 12.5%
On Tuesday, shares of ACADIA Pharmaceuticals traded near $25.5. The company has a market cap of approximately $4.34 billion and a P/E ratio of 11.46, indicating a relatively low valuation compared to earnings. ACADIA's beta of 0.83 suggests lower volatility compared to the market. The stock's 52-week range is between $19.69 and $28.35, with a 50-day moving average of $21.85 and a 200-day moving average of $23.24. The company maintains a strong financial position with a current ratio of 3.59 and a quick ratio of 3.27, alongside a debt-to-equity ratio of 4.07.
$ACAD price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
ACADIA Pharmaceuticals reported revenue of $1.1 billion, reflecting a growth rate of 9.7%. The company achieved an earnings per share (EPS) of $2.21, supported by a net margin of 34.3% and a return on equity (ROE) of 37.3%. Investors are looking forward to the next earnings report, scheduled for August 5, 2026.
Insider Buying and Selling at ACADIA Pharmaceuticals Inc.
Recent insider activity at ACADIA Pharmaceuticals includes a planned sale by Principal Accounting Officer Kihara James, who sold 11,421 shares at an average price of $26.08 on June 26, 2026. Notably, Baker Bros. Advisors LP acquired 69,252 shares in multiple transactions on May 29, 2026, without a specified price, indicating continued interest in the stock.
Analysts Set New Price Targets
Several analysts have maintained their positive outlook on ACADIA Pharmaceuticals. On June 30, 2026, B of A Securities maintained a buy rating with a $30 target. Citigroup and Canaccord Genuity also maintained buy ratings with targets of $35 and $36, respectively, on June 29, 2026. The consensus among 20 analysts is a buy rating, with an average target price of $32.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., based in San Diego, California, is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. It offers NUPLAZID, used for treating Parkinson's disease psychosis, and DAYBUE, for Rett syndrome. The company is also developing treatments for Alzheimer's disease psychosis, major depressive disorder, and other conditions. Led by CEO Catherine E. Owen Adams, ACADIA employs around 796 people.
Bottom Line
B of A Securities' reiterated buy rating and $30 price target reflect optimism about ACADIA Pharmaceuticals' prospects. Investors pay close attention to these analyst ratings as they provide insights into potential stock performance. However, it's important to remember that analyst opinions are just one piece of the investment puzzle.
Get ACADIA Pharmaceuticals Inc. alerts
New 13F filings, insider trades, and analyst moves on $ACAD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.